Research
    Xiaoming Xie
    Title Professor, Director of Breast Oncology Department Director of Laboratory of Cancer Biotechnology, State Key Laboratory of Oncology in Southern China
    Profile

    Dr. Xiaoming Xie is Surgeon and Chairman of the Department of Breast Oncology and Director of the Laboratory of Cancer Biotechnology in the State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center. Dr. Xie obtained his M.D. in 1986 and his Ph.D. in 1994 from Central South University. He later got postdoctoral training at the University of Navarra in Spain and University of Florida in USA. Dr.Xie worked as Research Associate in the Department of Immunology, Baylor College of Medicine, Houston, Texas, USA, during 1999 to 2003.

    Since 2003, Dr. Xie became Research Scientist and Translational Group Leader at the University of Texas MD Anderson Cancer Center, Texas. Dr. Xie has gained multiple awards including the AstraZeneca Award, USA (2005), the Best Prize of the 10th Annual Oncology Research Seminar. USA (2001), the Travel Grant of the 6th Conference on retroviruses and Opportunistic Infections, USA (1999) and the Best Oral Presentation Award of Terapia genica del hepatocarcinoma mediate la transferencia del gen la interlukina 12 y timidin kinasa mediada por adenovirus.Madrid, Spain (1998) as well as Dr. Sir Q.W. Lee fellowship. USA (1997).

    In 2008, he founded the Department of Breast Oncology in Sun Yat-sen University Cancer Center, Guangzhou, where he serves as the Chairman, Surgeon and Professor. His major research interests are targeted biotherapy for cancer, novel animal models for in vivo imaging, nanoparticle biotechnology, mechanism of development, metastasis and recurrence of breast cancer and basic and clinical research and clinical trial of breast cancer and clinical services (surgery and medical oncology).

    Dr. Xiaoming Xie has published more than 60 peer-reviewed articles (including Nature Cell Biology, Cancer Cell, Cancer Research) with 11 patents and 3 ongoing clinical trials at MD Anderson Cancer Center. He is specialized in multidisciplinary care of breast cancer and translational research and clinical trials, as well as the primary investigator and co-investigator of more than 20 ongoing research projects and clinical trails supported by various grants.

    Email xiexm@sysu.org.cn
    Phone Tel: 020-61639540(O), 13826109540 (Cell)Fax: 020-38320368
    Research Interest(s)

    1. Molecular biology of breast cancer/stem cells

    2. Living imaging animal models of breast cancer /stem cells

    3. Early diagnosis and biomarkers of breast cancer4. Nanoparticle-based targeted therapy

    Education

    1981 - 1986 MD, Central South University Xiangya Medical College ( Faculty of Medicine, Hunan Medical University)

    1990 – 1994 Ph.D., Molecular Virology and Oncology, Department of Internal medicine, Central South University Xiangya Medical College (Hunan Medical University)

    Publications

    Selected publications

    1. Xie, X., Xia, W., Li, Z., Kuo, H-P.,Liu, Y., Li, Z., Ding, Q., Zhang, S., Spohn, W., Yang, Y., Wei, Y., Lang, J-Y., Evans, D.B., Chiao, P.J., Abbruzzese J.L. and Hung, M-C. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell, 2007;12(July10):52-65. (IF: 26.925).

    2. Li L, Xie X, Luo J, Wei W , Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Yang M, Hung MC, X Xie (). Targeted Expression of miR-34a by T-VISA System Suppresses Tumor Cell Growth and Invasion in Breast Cancer. Mol Therapy; 2012; 20(12):2326-2334 (IF:6.873)

    3. Xie X, L Li, X Xiao, J Guo, Y Kong, M Wu, W Liu, G Gao, J L. Hsu, W Wei, M-C Hung () and X Xie(). Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther.2012 ;11(9);1915-1924. (IF:5.226)

    Last updated on: 2012

    Wang Jin
    Title Attending Surgeon
    Profile

    Dr. Jin Wang is attending surgeon of breast oncology in Sun Yat-Sen University Cancer Center (SYSUCC) and youth committee of Guangdong Province Medical Association. Dr. Wang got her M.D. from Chinese Academy of Medical Sciences and Peking Union Medical College in 2012. She then joined the Department of Breast Oncology at SYSUCC as a Surgical resident in August 2012. Dr. Wang specializes in the diagnosis and treatment of early-advanced breast cancer, as well as in oncoplastic surgery of breast tumor. Her major research interests include the mechanism of development and metastasis of breast cancer, nano particle biotechnology and target therapy. Dr. Wang has published nine academic papers as the first author, and obtained several funding as PI including ‘Medical Scientific Research Foundation of Guangdong Province’, ‘The Priming Scientific Research Foundation for the Junior Teachers of Medicine in Sun Yat-Sen University’, and ‘Foundation for Distinguished Young Talents in Sun Yat-Sen University Cancer Center’.

    Email wangjin1@sysucc.org.cn
    Phone 020-87343850
    Research Interest(s)

    Clinical services

    1. Diagnosis and Treatment of early and advanced breast cancer

     2. Oncoplastic Surgery of breast cancer


    Basic and Translational research

    1. Mechanism of development, metastasis and recurrence of breast cancer 

    2. Animal models for in vivo imaging

    3. Nanoparticle biotechnology

    4. Targeted biotherapy for breast cancer

    Education

    2009-2012 M.D. Surgery, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 

    2002-2009 M.M. 7-Year-Program Clinical Medicine, Harbin Medical University, Harbin, China

    Publications

    1. Wang J, Yu JC, Kang WM, et al. The predictive effect of cadherin-17 on lymph node micrometastasis in pN0 gastric cancer. Ann Surg Oncol. 2012;19(5):1529-34.(IF: 4.116)

    2. Wang J, Kang WM, Yu JC, et al. Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NF-κB signaling pathway. Cancer Biol Ther. 2013;14:3:262-70.(IF: 3.287)

    3. Wang J, Yu JC, Kang WM, et al. Superiority of a fish oil-enriched emulsion to medium-chain triacylglycerols/long-chain triacylglycerols in gastrointestinal surgery patients: a randomized clinical trial. Nutrition. 2012;28(6):623-9.(IF: 3.025)

    4. Wang J, Xiaoming Xie, Xi Wang, Jun Tang, Qingqing Pan, Yefan Zhang, Mengyang Di. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis. Surg Oncol. 2013;22:247-55.(IF: 2.444)

    5. Wang J, Yu JC, Kang WM, et al. Treatment strategy for early gastric cancer. Surg Oncol. 2012;21(2):119-23.(IF: 2.444)

    6. Wang J, Yu JC, Kang WM, et al. Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer. J Surg Oncol. 2012;105(4):400-4.(IF: 2.1)

    7. Wang J, Yu JC, Kang WM, et al. Laparoscopic partial splenectomy for giant hemangioma misdiagnosed as splenic cyst: a case report. Chin Med Sci J. 2010;25(3):189-92.

    8. Wang J, Yu JC, Kang WM, et al. Effects of Fish Oil Emulsion on Inflammation and its Clinical Practice. Chinese Journal of Practical Surgery. 2011;31(4):71-4. (Chinese)

    9. Wang J, Sun SB, Sun TW, et al. Expression and possible function of microRNA-21 in cirrhotic liver tissues. chinese journal of hepatology. 2009;17(1):74-5. (Chinese)

    Last updated on: 2013

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.